MIMI I-NAN HU to Carcinoma, Papillary
This is a "connection" page, showing publications MIMI I-NAN HU has written about Carcinoma, Papillary.
Connection Strength
0.047
-
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81.
Score: 0.024
-
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
Score: 0.023